Abera Bioscience
Abera Bioscience is a platform and vaccine development company with over 30 years of research experience in the medical, molecular, and microbiological fields. The company specializes in developing next-generation mucosal vaccines, including nasal vaccines against pneumococcal infections and influenza, aiming to improve vaccine efficacy and flexibility. Leveraging proprietary technology platforms, Abera is positioned to rapidly create new vaccine candidates, including for pandemic preparedness and influenza, where it aims to delay decision-making on virus strains for seasonal vaccines. The company is actively advancing its pipeline, which includes a universal pneumococcal vaccine candidate in clinical preparation, and is expanding into influenza and immuno-oncology. Abera has demonstrated success in developing nasal vaccines against viruses such as COVID-19 and is exploring the potential for mucosal immunization via nasal spray to prevent infection spread and outbreaks.
Industries
Abera Bioscience
Products
Nasal pneumococcal vaccine candidate (lead mucosal candidate)
An OMV-based nasal vaccine candidate intended to elicit mucosal and systemic immunity against pneumococcal infections; progressed through preclinical immunogenicity and toxicology studies and prepared for Phase I clinical planning.
Nasal influenza vaccine candidate (initiated development)
Influenza vaccine candidates using an OMV-based carrier and intranasal delivery formats (spray and powder) developed as part of seasonal and pandemic preparedness activities, with workflows designed to enable rapid candidate generation and later strain-selection.
Early-stage bacterial vaccine candidates (e.g., chlamydia, tuberculosis)
Multiple early pipeline vaccine candidates using OMV and related platform technologies for bacterial indications currently in preclinical development.
Nasal pneumococcal vaccine candidate (lead mucosal candidate)
An OMV-based nasal vaccine candidate intended to elicit mucosal and systemic immunity against pneumococcal infections; progressed through preclinical immunogenicity and toxicology studies and prepared for Phase I clinical planning.
Nasal influenza vaccine candidate (initiated development)
Influenza vaccine candidates using an OMV-based carrier and intranasal delivery formats (spray and powder) developed as part of seasonal and pandemic preparedness activities, with workflows designed to enable rapid candidate generation and later strain-selection.
Early-stage bacterial vaccine candidates (e.g., chlamydia, tuberculosis)
Multiple early pipeline vaccine candidates using OMV and related platform technologies for bacterial indications currently in preclinical development.
Services
Platform licensing and collaborative development
Licensing and collaborative R&D to apply a modular OMV-based vaccine platform in candidate development programs and indications outside the core pipeline.
Preclinical development and toxicology support
Design and execution of preclinical immunogenicity and GLP-style toxicology studies to generate data for regulatory submissions and clinical trial entry.
Process development and GMP manufacturing coordination
Development and verification of GMP-adapted production processes and coordination with contract manufacturers and test-bed facilities for scale-up and supply.
Formulation development for mucosal delivery (spray and powder)
Formulation R&D for nasal sprays and dry powders, including stability, manufacturability and delivery-format optimization.
Platform licensing and collaborative development
Licensing and collaborative R&D to apply a modular OMV-based vaccine platform in candidate development programs and indications outside the core pipeline.
Preclinical development and toxicology support
Design and execution of preclinical immunogenicity and GLP-style toxicology studies to generate data for regulatory submissions and clinical trial entry.
Process development and GMP manufacturing coordination
Development and verification of GMP-adapted production processes and coordination with contract manufacturers and test-bed facilities for scale-up and supply.
Formulation development for mucosal delivery (spray and powder)
Formulation R&D for nasal sprays and dry powders, including stability, manufacturability and delivery-format optimization.
Expertise Areas
- Mucosal vaccine development and intranasal delivery
- OMV-based vaccine platform engineering
- Formulation for nasal spray and dry powder delivery
- Preclinical efficacy and toxicology study execution
Key Technologies
- Outer membrane vesicle (OMV) vaccine vectors
- Modular protein-tag antigen coupling
- Cell-free protein synthesis for antigen production
- Nasal spray and dry powder formulation technologies